Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Cell Carcinoma of Head and Neck 4 Head and Neck Neoplasms 4 Glioblastoma 4 Carcinoma, Hepatocellular 4 Brain Neoplasms 4 Lung Neoplasms 3 Glioma 3 Carcinoma, Non-Small-Cell Lung 3 Small Cell Lung Carcinoma 2 Sarcoma 2 Neoplasms 2 Liver Neoplasms 2 Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Unspecified Adult Solid Tumor, Protocol Specific 1 Triple Negative Breast Neoplasms 1 Tongue Neoplasms 1 Stage III Lung Non-Small Cell Cancer AJCC v7 1 Skin Neoplasms 1 Salivary Gland Neoplasms 1 Rectal Neoplasms 1 Oropharyngeal Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Neoplasms 1 Mouth Neoplasms 1 Meningioma 1 Melanoma 1 Liver Cirrhosis 1 Laryngeal Neoplasms 1 Hypoxia 1

Interventions

pembrolizumab 300 Nivolumab 273 Ipilimumab 250 aldesleukin 137 Cyclophosphamide 136 Interleukin-2 105 trametinib 82 dabrafenib 76 Temozolomide 75 Dacarbazine 74 Vemurafenib 71 fludarabine 68 fludarabine phosphate 62 Biopsy 49 binimetinib 47 sargramostim 44 Radiosurgery 44 Bevacizumab 43 Paclitaxel 42 encorafenib 40 incomplete Freund's adjuvant 39 atezolizumab 38 Radiotherapy 37 Cisplatin 36 CTLA-4 Antigen 36 Specimen Handling 35 Magnetic Resonance Spectroscopy 35 Carboplatin 35 cobimetinib 34 Introns 33

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma × fluoromisonidazole × Clear all

NCT02061007 2016-05-09

Biomarker Correlates of Hypoxia in Metastatic Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Withdrawn

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡